124 related articles for article (PubMed ID: 2109697)
1. Immunocytochemical localization of sphingolipid activator protein 2 (SAP-2) in normal and SAP-deficient fibroblasts.
Paton BC; Hughes JL; Harzer K; Poulos A
Eur J Cell Biol; 1990 Feb; 51(1):157-64. PubMed ID: 2109697
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor.
Burkhardt JK; Hüttler S; Klein A; Möbius W; Habermann A; Griffiths G; Sandhoff K
Eur J Cell Biol; 1997 May; 73(1):10-8. PubMed ID: 9174667
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo.
Klein A; Henseler M; Klein C; Suzuki K; Harzer K; Sandhoff K
Biochem Biophys Res Commun; 1994 May; 200(3):1440-8. PubMed ID: 8185598
[TBL] [Abstract][Full Text] [Related]
4. Processing of sphingolipid activator proteins and the topology of lysosomal digestion.
Sandhoff K; Kolter T
Acta Biochim Pol; 1998; 45(2):373-84. PubMed ID: 9821868
[TBL] [Abstract][Full Text] [Related]
5. Human sphingolipid activator protein-1 and sphingolipid activator protein-2 are encoded by the same gene.
Reiner O; Dagan O; Horowitz M
J Mol Neurosci; 1989; 1(4):225-33. PubMed ID: 2484333
[TBL] [Abstract][Full Text] [Related]
6. Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.
Paton BC; Schmid B; Kustermann-Kuhn B; Poulos A; Harzer K
Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):481-8. PubMed ID: 1637339
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses.
Harzer K; Paton BC; Poulos A; Kustermann-Kuhn B; Roggendorf W; Grisar T; Popp M
Eur J Pediatr; 1989 Oct; 149(1):31-9. PubMed ID: 2514102
[TBL] [Abstract][Full Text] [Related]
8. Saposin C is required for lipid presentation by human CD1b.
Winau F; Schwierzeck V; Hurwitz R; Remmel N; Sieling PA; Modlin RL; Porcelli SA; Brinkmann V; Sugita M; Sandhoff K; Kaufmann SH; Schaible UE
Nat Immunol; 2004 Feb; 5(2):169-74. PubMed ID: 14716313
[TBL] [Abstract][Full Text] [Related]
9. Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease Type C.
Fujibayashi S; Wenger DA
Clin Chim Acta; 1985 Mar; 146(2-3):147-56. PubMed ID: 3921288
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical localization of sphingolipid activator protein-1, the sulfatide/GM1 ganglioside activator, to lysosomes in human liver and colon.
Tamaru T; Fujibayashi S; Brown WR; Wenger DA
Histochemistry; 1986; 86(2):195-200. PubMed ID: 3028990
[TBL] [Abstract][Full Text] [Related]
11. Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant.
Pàmpols T; Pineda M; Girós ML; Ferrer I; Cusi V; Chabás A; Sanmarti FX; Vanier MT; Christomanou H
Acta Neuropathol; 1999 Jan; 97(1):91-7. PubMed ID: 9930900
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.
Schmid B; Paton BC; Sandhoff K; Harzer K
Hum Genet; 1992 Jul; 89(5):513-8. PubMed ID: 1634229
[TBL] [Abstract][Full Text] [Related]
13. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.
Bradová V; Smíd F; Ulrich-Bott B; Roggendorf W; Paton BC; Harzer K
Hum Genet; 1993 Sep; 92(2):143-52. PubMed ID: 8370580
[TBL] [Abstract][Full Text] [Related]
14. Clinical, pathological, and biochemical studies on an infantile case of sulfatide/GM1 activator protein deficiency.
Wenger DA; DeGala G; Williams C; Taylor HA; Stevenson RE; Pruitt JR; Miller J; Garen PD; Balentine JD
Am J Med Genet; 1989 Jun; 33(2):255-65. PubMed ID: 2764035
[TBL] [Abstract][Full Text] [Related]
15. Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell.
Sandhoff K; Kolter T; Van Echten-Deckert G
Ann N Y Acad Sci; 1998 Jun; 845():139-51. PubMed ID: 9668348
[TBL] [Abstract][Full Text] [Related]
16. Pathological study of mice with total deficiency of sphingolipid activator proteins (SAP knockout mice).
Oya Y; Nakayasu H; Fujita N; Suzuki K; Suzuki K
Acta Neuropathol; 1998 Jul; 96(1):29-40. PubMed ID: 9678511
[TBL] [Abstract][Full Text] [Related]
17. Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.
Tohyama J; Oya Y; Ezoe T; Vanier MT; Nakayasu H; Fujita N; Suzuki K
J Inherit Metab Dis; 1999 Jun; 22(5):649-62. PubMed ID: 10399097
[TBL] [Abstract][Full Text] [Related]
18. [Sphingolipid activator protein deficiency].
Inui K
Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):756-9. PubMed ID: 3270890
[No Abstract] [Full Text] [Related]
19. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene.
Schnabel D; Schröder M; Fürst W; Klein A; Hurwitz R; Zenk T; Weber J; Harzer K; Paton BC; Poulos A
J Biol Chem; 1992 Feb; 267(5):3312-5. PubMed ID: 1371116
[TBL] [Abstract][Full Text] [Related]
20. Correction of sulfatide metabolism after transfer of prosaposin cDNA to cultured cells from a patient with SAP-1 deficiency.
Rafi MA; Amini S; Zhang XL; Wenger DA
Am J Hum Genet; 1992 Jun; 50(6):1252-8. PubMed ID: 1350885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
